ReviewBiomedicines2021
Inhaled Corticosteroids and the Lung Microbiome in COPD.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Inhaled Corticosteroids and Non-Tuberculous Mycobacteria Risk in Patients with COPD.Journal of clinical medicine · 2026Article
- Longitudinal change of lung microbiome in chronic obstructive pulmonary disease: a prospective cohort study.Respiratory research · 2026Article
- The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.Frontiers in immunology · 2026Review
- Metagenome and metabolome study on inhaled corticosteroids in asthma patients with side effects.Journal of integrative bioinformatics · 2025Article
- The role and mechanism of lung microbiota in coal mine dust-induced NLRP3 inflammasome upregulate and lung injury.Scientific reports · 2025Article
- Effect of benralizumab treatment on the airway microbiome in COPD.ERJ open research · 2025Article
- Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL.International journal of chronic obstructive pulmonary disease · 2025Article
- Macrophages and the microbiome in chronic obstructive pulmonary disease.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Inhaled Corticosteroids and the Risk of Nontuberculous Mycobacterial Infection in Chronic Airway Disease: A Nationwide Population-Based Study.Tuberculosis and respiratory diseases · 2024Article
- Reexamining Chronic Obstructive Pulmonary Disease in Bronchiectasis: Elucidating Overdiagnosis and Outcomes from EMBARC's ROSE Criteria.American journal of respiratory and critical care medicine · 2024Article
- Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy.Heliyon · 2024Review
- Tobacco use, self-reported professional dental cleaning habits, and lung adenocarcinoma diagnosis are associated with bronchial and lung microbiome alpha diversity.Respiratory research · 2024Article
- A Systematic Review of the Pulmonary Microbiome in Patients with Acute Exacerbation COPD Requiring ICU Admission.Journal of clinical medicine · 2024Review
- Inhaled corticosteroids and risk of lower respiratory tract infection withBMJ open respiratory research · 2023Observational
- Rational use of inhaled corticosteroids for the treatment of COPD.NPJ primary care respiratory medicine · 2023Review
- Effects of Fluticasone Propionate onmSphere · 2022Article
- Review
- Respiratory and Intestinal Microbiota in Pediatric Lung Diseases-Current Evidence of the Gut-Lung Axis.International journal of molecular sciences · 2022Review
- Journal Club: Biologics and Potential for Immune Modulation in Chronic Obstructive Lung Disease.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The Global Initiative for Chronic Obstructive Lung Disease 2021 Report recommends inhaled corticosteroid (ICS)-containing regimens as part of pharmacological treatment in patients with chronic obstructive lung disease (COPD) and frequent exacerbations, particularly with eosinophilic inflammation. However, real-world studies reveal overprescription of ICS in COPD, irrespective of disease presentation and inflammatory endotype, leading to increased risk of side effects, mainly respiratory infections. The optimal use of ICS in COPD therefore remains an area of intensive research, and additional biomarkers of benefit and risk are needed. Although the interplay between inflammation and infection in COPD is widely acknowledged, the role of the microbiome in shaping lower airway inflammation has only recently been explored. Next-generation sequencing has revealed that COPD disease progression and exacerbation frequency are associated with changes in the composition of the lung microbiome, and that the immunosuppressive effects of ICS can contribute to potentially deleterious airway microbiota changes by increasing bacterial load and the abundance of potentially pathogenic taxa such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.